← Back to Search

Neuraminidase Inhibitor

Zanamivir for Type 2 Diabetes (NAED Trial)

Phase 2
Waitlist Available
Led By Luis Martinez-Lemus, PhD
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of T2D classified based on physician diagnosis
Men and women with a BMI of 25-39 kg/m2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 and 5 days
Awards & highlights

NAED Trial Summary

This trial is testing whether the drug zanamivir can help improve the function of blood vessels in people with type 2 diabetes.

Who is the study for?
This trial is for adults aged 45-64 with Type 2 Diabetes, a BMI of 25-39 kg/m2, and no severe health issues like active cancer or heart disease. It's not for pregnant women, smokers, those with allergies to lactose or milk proteins, heavy drinkers, or people on certain medications.Check my eligibility
What is being tested?
The study tests if Zanamivir can improve blood vessel function in Type 2 Diabetes patients. Participants will receive Zanamivir to see if it helps their condition by inhibiting neuraminidase activity.See study design
What are the potential side effects?
Zanamivir may cause side effects such as headaches, nausea, diarrhea, bronchitis-like symptoms (coughing and trouble breathing), ear/nose/throat infections; however specific risks related to this trial are not detailed.

NAED Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with type 2 diabetes by a doctor.
Select...
My BMI is between 25 and 39.
Select...
I am between 45 and 64 years old.

NAED Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 and 5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 and 5 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in glycocalyx integrity
Secondary outcome measures
Change in Vascular function

Side effects data

From 2009 Phase 3 trial • 64 Patients • NCT00784784
10%
pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Influenza Vaccine
Antiviral Prophylaxis

NAED Trial Design

1Treatment groups
Experimental Treatment
Group I: Zanamivir treatmentExperimental Treatment1 Intervention
Study participants will receive 5 days of treatment with a zanamivir inhaler.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zanamivir
2009
Completed Phase 3
~1050

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
365 Previous Clinical Trials
628,223 Total Patients Enrolled
Luis Martinez-Lemus, PhDPrincipal InvestigatorUniversity of Missouri, School of Medicine

Media Library

Zanamivir (Neuraminidase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04867707 — Phase 2
Type 2 Diabetes Research Study Groups: Zanamivir treatment
Type 2 Diabetes Clinical Trial 2023: Zanamivir Highlights & Side Effects. Trial Name: NCT04867707 — Phase 2
Zanamivir (Neuraminidase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04867707 — Phase 2
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top